Commerce Bank acquired a new stake in Natera, Inc. (NASDAQ:NTRA - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 4,331 shares of the medical research company's stock, valued at approximately $1,176,000.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Horizon Investments LLC raised its position in Natera by 22.0% during the fourth quarter. Horizon Investments LLC now owns 244 shares of the medical research company's stock worth $56,000 after acquiring an additional 44 shares in the last quarter. Parallel Advisors LLC grew its position in shares of Natera by 5.5% in the 1st quarter. Parallel Advisors LLC now owns 905 shares of the medical research company's stock valued at $181,000 after acquiring an additional 47 shares during the period. First Horizon Corp grew its position in shares of Natera by 5.5% in the 1st quarter. First Horizon Corp now owns 982 shares of the medical research company's stock valued at $196,000 after acquiring an additional 51 shares during the period. Siemens Fonds Invest GmbH increased its stake in shares of Natera by 3.1% during the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company's stock worth $290,000 after purchasing an additional 54 shares during the last quarter. Finally, Alamea Verwaltungs GmbH increased its stake in shares of Natera by 2.9% during the 4th quarter. Alamea Verwaltungs GmbH now owns 2,229 shares of the medical research company's stock worth $515,000 after purchasing an additional 62 shares during the last quarter. 99.90% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Several equities research analysts recently issued reports on NTRA shares. UBS Group set a $260.00 target price on shares of Natera in a research note on Wednesday, June 24th. Barclays reissued an "overweight" rating and set a $340.00 price target on shares of Natera in a research report on Friday, August 7th. Stephens upped their price objective on Natera from $305.00 to $350.00 and gave the company an "overweight" rating in a research note on Wednesday, August 12th. Morgan Stanley reaffirmed an "overweight" rating and issued a $355.00 price objective on shares of Natera in a research report on Monday, August 10th. Finally, JPMorgan Chase & Co. lifted their target price on Natera from $315.00 to $360.00 and gave the stock an "overweight" rating in a research note on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Natera has a consensus rating of "Moderate Buy" and an average price target of $319.38.
Read Our Latest Stock Analysis on NTRA
Natera Stock Performance
NASDAQ NTRA opened at $336.71 on Wednesday. The stock has a market cap of $48.53 billion, a PE ratio of -247.58 and a beta of 1.51. The firm has a 50-day moving average of $278.79 and a 200-day moving average of $231.01. Natera, Inc. has a 52-week low of $157.43 and a 52-week high of $337.12.
Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The business had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. During the same quarter in the prior year, the business earned ($0.74) EPS. Natera's quarterly revenue was up 37.7% on a year-over-year basis. As a group, analysts predict that Natera, Inc. will post -1.02 EPS for the current fiscal year.
Insider Transactions at Natera
In related news, Director Gail Boxer Marcus sold 11,000 shares of the firm's stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the transaction, the director directly owned 6,183 shares of the company's stock, valued at approximately $1,343,009.43. This trade represents a 64.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Solomon Moshkevich sold 3,410 shares of the business's stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $265.58, for a total transaction of $905,627.80. Following the completion of the sale, the insider directly owned 129,019 shares of the company's stock, valued at $34,264,866.02. This represents a 2.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 177,955 shares of company stock worth $40,704,193. 5.05% of the stock is currently owned by company insiders.
About Natera
(
Free Report)
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Natera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.
While Natera currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
